The Clinical Trial Risk Tool has been featured in a guest column in Clinical Leader, titled A Tool To Tackle The Risk Of Uninformative Trials, in cooperation with Abby Proch, Executive Editor at Clinical Leader.
In the article, Thomas Wood of Fast Data Science highlights the problem of “uninformative” clinical trials – those that don’t provide meaningful results, even if the drug being tested is effective or ineffective. He distinguishes these from simply “failed” trials and emphasises the ethical and financial waste they represent. Wood explains that while “uninformativeness” lacks a formal definition, it can be understood by examining the five conditions of an “informative” trial as outlined by Zarin, Goodman, and Kimmelman (2019): addressing an important question, meaningful design, feasibility, scientific validity, and timely, accurate reporting. Trials excluded from meta-analyses due to bias are often considered uninformative.
Wood describes how the Clinical Trial Risk Tool tackles this problem by assessing trial protocols against these criteria. He suggests expanding the tool to include a template clinical trial budget derived from real-world cost data (e.g., Sunshine Act disclosures). Further enhancements could include identifying endpoints and inclusion/exclusion criteria, then searching clinical trial registries (like ClinicalTrials.gov) for similar past trials to help users evaluate their planned trial’s design choices.
Wood also suggests tailoring the tool for different user profiles (patient advocates, financial planners, medical professionals) by providing personalised feedback and recommended actions for protocol improvement. The goal is not to replace human review, but to help users identify design gaps and high-risk indicators early in the process.
Fast Data Science is a leading data science consultancy firm providing bespoke machine learning solutions for businesses of all sizes across the globe, with a concentration on the pharmaceutical and healthcare industries.
You may have been tasked with creating a clinical trial site budget. This is a budget itemising all the costs that will be incurred at the study site. The site budget may be needed To estimate the total cost of that site running part of the trial, as part of a bid to the CRO or sponsor To identify who needs to be reimbursed for each cost item To ascertain whether or not it is feasible to run the trial at that site To ensure that the site is reimbursed for the costs that they incur while running the trial If you are building a site budget, the most important document is the study protocol.
Fast Data Science are pleased to announce that the Clinical Trial Risk Tool, has been accepted as a supplier on the UK Government’s G-Cloud 15 framework. The G-Cloud 15 framework allows public sector bodies to buy cloud-based computing services such as AI, hosting, software and support directly without lengthy, costly traditional tender processes. What does the Clinical Trial Risk Tool do? The Clinical Trial Risk Tool helps users to analyse clinical trial protocols and documents.
Estimating the total cost of a clinical trial before it runs is challenging. Public data on past trial costs can be hard to come by, as many companies guard this information carefully. Trials in high income countries and low and middle income countries have very different costs. Upload your clinical trial protocol and create a cost benchmark with AI Protocol to cost benchmark The Clinical Trial Risk Tool uses AI and Natural Language Processing (NLP) to estimate the cost of a trial using the information contained in the clinical trial protocol.
